Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2017-09-22 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2017-09-22 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-09-22 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a loan and promissory note, which is a financing activity. The document is relatively short (3658 characters) and focuses on the announcement of a financing transaction rather than detailed financial results or comprehensive financial statements. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2017-07-20 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-07-17 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-07-17 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 11, 2017. It reports two main events: (1) a private placement of equity securities (unregistered sales of equity securities) completed on July 12, 2017, including details of the units sold and total proceeds, and (2) the appointment of a new Chief Financial Officer, Robert Wolfe, effective July 11, 2017. The content focuses on financing activity (private placement) and management change (CFO appointment). The private placement is a capital raising event, and the CFO appointment is a management change. However, the primary focus and detailed disclosure is on the private placement offering, which is a financing update. According to the filing definitions, updates on company fundraising and financing activities fall under Capital/Financing Update (CAP). The management appointment could suggest Board/Management Information (MANG), but since the document covers both and the private placement is the material definitive agreement and main event, CAP is the best fit. The document is not an annual or quarterly report, nor an earnings release, nor a proxy or voting announcement. It is a current report on material events, specifically a financing event and management appointment. Confidence is high given the clear description of the private placement and the nature of the 8-K filing.
2017-07-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.